Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

(2015) S. Verstovsek et al.   HAEMATOLOGICA

Thrombopoiesis

(2015) Kenneth Kaushansky   SEMINARS IN HEMATOLOGY

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

(2015) S. Verstovsek et al.   HAEMATOLOGICA

Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis

(2014) Ramy A. Abdelrahman et al.   BRITISH JOURNAL OF HAEMATOLOGY

An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms

(2014) A Tefferi et al.   LEUKEMIA

An Immune Dysregulation in MPN

(2014) Giovanni Barosi   Current Hematologic Malignancy Reports

Therapy for myeloproliferative neoplasms: when, which agent, and how?

(2014) H. L. Geyer et al.   Hematology-American Society of Hematology Education Program

Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing

(2013) Ruben A Mesa et al.   Journal of Hematology & Oncology

Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts

(2013) Moshe Talpaz et al.   Journal of Hematology & Oncology

Whole blood transcriptional profiling reveals significant down-regulation of human leukocyte antigen class I and II genes in essential thrombocythemia, polycythemia vera and myelofibrosis

(2013) Vibe Skov et al.   LEUKEMIA & LYMPHOMA

JAK2 Inhibitors for Myelofibrosis: Why are They Effective in Patients with and Without JAK2V617F Mutation?

(2012) Fabio P. S. Santos et al.   Anti-Cancer Agents in Medicinal Chemistry

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

(2012) S. Verstovsek et al.   BLOOD

Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis

(2011) Vibe Skov et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis

(2011) Ayalew Tefferi et al.   NEW ENGLAND JOURNAL OF MEDICINE

The JAK2 V617F somatic mutation, mortality and cancer risk in the general population

(2010) C. Nielsen et al.   HAEMATOLOGICA